Therapy Areas: AIDS & HIV
Sagent Pharmaceuticals adds Camostat mesilate to ACTIV-2 Adaptive Platform Treatment Trial for COVID-19
15 February 2021 -

Sagent Pharmaceuticals, a Nichi-Iko Group Company, announced on Friday that Camostat mesilate (Camostat) has been added to the present ACTIV-2 Adaptive Platform Treatment Trial intended for outpatients with COVID-19 (Adapt Out COVID) that was introduced by the National Institutes of Health (NIH) and the AIDS Clinical Trials Group (ACTG) in May 2020.

The trial will continue to assess monoclonal antibodies and other small molecules for outpatient COVID treatment. The product is the first orally administered agent to be included in the outpatient Adapt Out COVID trial.

Adapt Out COVID is a randomised, blinded, controlled adaptive platform trial that enables addition of investigational agents over the course of the study, in order to efficiently test a variety of new agents against placebo within the same trial infrastructure. It also intends to determine if they are able to reduce viral shedding, thereby potentially preventing transmission of SARS-CoV-2 (the virus that causes COVID-19). The first oral dose of the product will be taken by the subjects at the enrolment visit and subsequent doses at home.



Related Headlines